Humanized Liver Mice Models Market Overview
The Humanized Liver Mice Models Market is expanding as pharmaceutical and biotechnology companies increasingly seek advanced preclinical models for drug development, toxicology testing, disease modeling, and gene therapy research. Rising demand for personalized medicine, increasing prevalence of liver diseases, advancements in genetic engineering, growing research investments, and the need for more accurate human-relevant models are supporting market growth.
According to the WiseGuyReports market report published in December 2025, the global Humanized Liver Mice Models Market was valued at USD 935.9 Million in 2024 and is projected to grow from USD 1.023 Billion in 2025 to USD 2.5 Billion by 2035, registering a CAGR of 9.3% during 2025–2035. North America held the leading regional position, valued at USD 410 Million in 2024 and projected to reach USD 1 Billion by 2035. Drug Development was the leading application segment, valued at USD 400 Million in 2024 and projected to reach USD 1 Billion by 2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=617551
Key players driving innovation and competitiveness in the Humanized Liver Mice Models Market include:
XenoTech
AstraZeneca
Thermo Fisher Scientific
Taconic Biosciences
Horizon Discovery
JAX Labs
Crown Bioscience
OncoOne
Envigo
Sanofi
Evotec
Charles River Laboratories
Pfizer
genOway
Novartis
The market is being shaped by increasing demand for accurate drug testing platforms, growing investment in liver disease research, and advancements in biotechnology. Genetic engineering technologies such as CRISPR and genome editing are enabling researchers to develop more sophisticated models that better replicate human liver functions and disease mechanisms. Growing pharmaceutical R&D activity and the expansion of personalized medicine are further increasing the use of humanized liver mice models in preclinical research.
The Humanized Liver Mice Models Market can be segmented by Application into Drug Development, Toxicology Testing, Disease Modeling, and Gene Therapy Research. By Research Type, it includes Academic Research, Pharmaceutical Research, and Biotechnology Research. By End User, it covers Pharmaceutical Companies, Biotechnology Firms, and Research Institutions. Regionally, the market covers North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
The growing need for more predictive and human-relevant preclinical models is creating opportunities for pharmaceutical companies, biotechnology firms, research institutions, and model-development specialists. Customized disease models, CRISPR-based genetic engineering, precision medicine research, advanced toxicology testing, and strategic collaborations can support market differentiation and future growth.
Recent Developments and Market Trends:
Advancements in genetic engineering, including CRISPR and genome-editing technologies, are improving the customization and physiological relevance of humanized liver mice models.
Drug development remains a major application as pharmaceutical companies seek improved approaches for evaluating drug efficacy, metabolism, and safety before clinical trials.
The growing focus on personalized medicine is increasing demand for models that can better represent human-specific biological responses.
Collaborations between pharmaceutical companies, biotechnology firms, and research institutions are supporting the development and adoption of advanced humanized liver models.
In March 2025, Taconic Biosciences announced the acquisition of XenoTech to expand its humanized liver mouse model portfolio and strengthen its hepatotropic disease research capabilities.
In June 2025, Sanofi expanded its collaboration with Evotec to integrate validated humanized liver mouse models into early-stage drug discovery programs for liver-related diseases.
Reasons to Buy the Report:
Provides comprehensive insights into the Humanized Liver Mice Models Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across drug development, toxicology testing, disease modeling, and gene therapy research.
Offers detailed segmentation analysis across application, research type, end user, and geographic markets.
Includes competitive intelligence covering leading pharmaceutical, biotechnology, research, and humanized-model companies.
Supports informed decisions using market forecasts, personalized medicine trends, genetic engineering advancements, liver disease research, R&D investments, and regional opportunities.
Future Outlook:
The future of the Humanized Liver Mice Models Market will be shaped by increasing pharmaceutical R&D investments, growing demand for personalized medicine, advancements in genetic engineering, rising liver disease research, and the need for more accurate preclinical testing models. Drug Development is expected to remain a leading application, with the segment projected to increase from USD 400 Million in 2024 to USD 1 Billion by 2035. North America is expected to retain its leadership position, with the regional market projected to grow from USD 410 Million in 2024 to USD 1 Billion by 2035. Asia Pacific is positioned for strong growth as biotechnology research, pharmaceutical development, and investment in advanced drug-testing models increase. The global Humanized Liver Mice Models Market is projected to reach USD 2.5 Billion by 2035 at a CAGR of 9.3%.
➤➤Explore Our Latest Related Reports:
